← Back to Search

Checkpoint Inhibitor

WT1 Vaccine for Ovarian Cancer

Phase 1
Waitlist Available
Led By Roisin O'Cearbhaill, MB BCh BAO
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing the safety of two different cancer vaccines in combination with nivolumab, an immunotherapy drug.

Eligible Conditions
  • Recurrent Ovarian Cancer
  • Ovarian Cancer
  • Fallopian Tubes
  • Peritoneal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose limiting toxicity (DLT)
Secondary outcome measures
immune response (cohort 2)
progression-free survival rate (cohort 2)

Trial Design

2Treatment groups
Experimental Treatment
Group I: WT1 Vaccine and NivolumabExperimental Treatment2 Interventions
Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab every two weeks over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.This cohort has completed recruitment.
Group II: ESO-1 Vaccine and NivolumabExperimental Treatment2 Interventions
Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NY-ESO-1 Vaccine
2016
Completed Phase 1
~20
WT1 Vaccine
2016
Completed Phase 1
~20
Nivolumab
FDA approved

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,935 Previous Clinical Trials
588,844 Total Patients Enrolled
72 Trials studying Ovarian Cancer
42,957 Patients Enrolled for Ovarian Cancer
Roisin O'Cearbhaill, MB BCh BAOPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many geographically distinct venues is this clinical experiment taking place?

"There are 7 clinical trial sites offering this protocol. Two of these locations, Memorial Sloan Kettering Commack and Memorial Sloan Kettering Cancer Center in New york have been designated as primary centres for the study's activities. Additional medical facilities include Memorial Sloan Kettering Bergen in Montvale and 4 other locales."

Answered by AI

Does this research endeavor mark a new precedent in medicine?

"Currently, there are 717 ongoing experiments involving the WT1 Vaccine in 2356 cities and 49 nations. The first clinical trial happened back in 2012, sponsored by Ono Pharmaceutical Co. Ltd., which administered it to 659 participants over Phases 1 & 2 of drug approval. Since then, 252 investigations have since been concluded."

Answered by AI

Has there been a previous examination of the WT1 Vaccine's efficacy?

"The WT1 Vaccine was first studied in 2012 at Local Institution, with 252 trials already concluded. Currently, 717 studies are recruiting patients; many of which occur in Commack, New york."

Answered by AI

How efficacious is the WT1 Vaccine in providing health benefits to patients?

"The limited data available concerning WT1 Vaccine's efficacy and safety ratings warrants a score of 1 on the risk scale."

Answered by AI

What medical conditions typically necessitate WT1 Vaccine treatment?

"WT1 Vaccine is typically utilized for malignant neoplasms, but also holds promise in the treatment of unresectable melanoma, squamous cell carcinoma and metastatic esophageal adenocarcinoma."

Answered by AI

Is enrollment for this investigation open at the present time?

"A cursory glance at clinicaltrials.gov reveals that this medical trial is not recruiting any additional participants; indeed, the study was last updated on August 2nd 2022 and originally posted 4 years prior. Despite its inactivity, there are still 2362 other trials actively searching for patients."

Answered by AI

How many participants have joined this research endeavor?

"This clinical trial is no longer actively seeking participants, with the most recent update occurring on August 2nd 2022. However, if you are looking for alternative studies there are 1645 trials which involve fallopian tubes and 717 trials involving a WT1 Vaccine that require enrolment of patients."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
2016. "A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02737787.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top